# The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

> **NCT00392171** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 120 (actual)

## Conditions studied

- Glioma
- Astrocytoma
- Oligodendroglioma
- Glioblastoma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00392171
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-09
- **Primary completion:** 2009-09-15
- **Final completion:** 2009-09-15
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392171, "The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00392171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*